SLC31A1 and ovarian carcinoma: It was found that combining EGCG (10 μM) with Cisplatin would enhance the sensitivity of ovarian cancer cells to the chemotherapeutic agent by inducing copper transporter 1 (CTR1) protein expression and by blocking its degradation in OVCAR3 and SKOV3 cells as well as xenograft mice.